Alemanno Sophia, Jaksch Peter, Benazzo Alberto
Vienna Lung Transplant Program, Department of Thoracic Surgery, Medical University of Vienna, Vienna, Austria.
Transplant Direct. 2025 Sep 2;11(9):e1831. doi: 10.1097/TXD.0000000000001831. eCollection 2025 Sep.
Extracorporeal photopheresis (ECP) is an immunomodulatory therapy currently used as an add-on treatment for the prevention and management of organ rejection in lung transplantation. Thanks to its immunomodulatory properties and its ability to reduce the need for immunosuppressive therapies, ECP presents a promising therapeutic option, especially for high-risk patients with comorbidities, infections, or malignancies. This review provides a comprehensive overview of the current indications, clinical experience, and ongoing research surrounding the use of ECP in lung transplantation. Additionally, it delves into the current understanding of the mechanism of action of ECP, its potential role in lung transplantation, and the limitations identified in existing studies. By highlighting these aspects, the review aims to lay the groundwork for future research, which could further elucidate the mechanisms underlying this promising therapy and contribute to the standardization of therapeutic protocols.
体外光化学疗法（ECP）是一种免疫调节疗法，目前作为附加治疗用于肺移植中器官排斥反应的预防和管理。由于其免疫调节特性以及减少免疫抑制疗法需求的能力，ECP是一种有前景的治疗选择，尤其对于患有合并症、感染或恶性肿瘤的高危患者。本综述全面概述了ECP在肺移植中的当前适应证、临床经验及正在进行的研究。此外，还深入探讨了目前对ECP作用机制的理解、其在肺移植中的潜在作用以及现有研究中发现的局限性。通过强调这些方面，本综述旨在为未来研究奠定基础，这可能会进一步阐明这种有前景疗法的潜在机制，并有助于治疗方案的标准化。
